ann out, page-4

ASX and Media release
Approval to commence final patient group using CAVATAK?
in Intravenous Phase I Melanoma, Breast or Prostate trial.
5th April 2011, Sydney: Viralytics Limited (ASX: VLA, OTC: VRACY) is pleased to announce that following a meeting of the Independent Data Safety Monitoring Committee, the Company has been granted approval to commence the administration of the highest dosing level of CAVATAK? in the final group of patients with late stage Melanoma, Breast or Prostate cancer in the Phase I intravenous study.
The final group of two patients will receive a single intravenous infusion of CAVATAK? at a dose of 1010 infectious units, which is 10 times higher than that given to the previous patient group and 10,000 times greater than that administered to the first group of patients in the current trial.
The primary objective of this study is to generate the necessary safety data to allow more progressive clinical assessment of CAVATAK? in a variety of cancer indications that are best targeted using a strategy of intravenous administration.
?Effective intravenous delivery of CAVATAK? allows potential targeting of a range of solid cancer types found throughout the human body which are not readily accessible for direct injection. To date, intravenous administration of CAVATAK? has been well tolerated and the completion of this study will provide the company with a sound base to progress into a more advanced clinical evaluation program? said Professor Shafren, the Company‟s chief Scientific Officer.